Abstract 775P
Background
Pathology-defined omental CRS after neoadjuvant chemotherapy (NACT) predicts survival outcomes in women with newly diagnosed FIGO stage IIIC/IV HGSOC. HRD-positive tumours have a superior response to PARPi therapy compared to HRD-negative tumours. We investigated the association between CRS and tHRD to assess CRS as a cost-free, potential biomarker for PARPi efficacy.
Methods
Eligible women included those with newly diagnosed FIGO stage IIIC/IV HGSOC treated with NACT and tested using Myriad’s myChoice® tHRD assay at The Christie Hospital between April 2021 and December 2023. Univariable and multivariable (MV) Cox proportional hazards models were developed to validate the association between survival outcomes and key clinical factors. The association between CRS3 (no/minimal residual tumour) and tHRD was assessed using the chi-squared test.
Results
315 women were included in the overall population (median age 67, range 36-91). 89 (28%) had FIGO stage IVB disease and 47 (15%) had a tBRCA1/2 mutation. 197 (63%) received 3-weekly carboplatin-paclitaxel. MV analysis of the overall population showed that undergoing primary cytoreductive surgery (yes vs. no) was prognostic (P
Conclusions
We found an association between tHRD and omental CRS in women with newly diagnosed FIGO stage IIIC/IV HGSOC treated with NACT and DPS. CRS should be evaluated in a prospective study as a biomarker of PARPi efficacy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Christie NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
870P - POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
Presenter: Martin Forster
Session: Poster session 02
871P - Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study
Presenter: Lara Iglesias Docampo
Session: Poster session 02
873P - Nivolumab (NIVO) in the first-line (1L) or second-line (2L) and later (2L+) settings in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from the German non-interventional study (NIS), HANNA
Presenter: Andreas Dietz
Session: Poster session 02
874P - Preliminary outcomes from a phase Ib/II study of WX390 combined with toripalimab in patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Ye Guo
Session: Poster session 02
875P - A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Dongmei Ji
Session: Poster session 02
876P - Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Xiaozhong Chen
Session: Poster session 02
878P - Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+ oropharyngeal cancer that progressed with prior anti-PD-1 therapy
Presenter: Anthony Kong
Session: Poster session 02
879P - VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Presenter: Jared Weiss
Session: Poster session 02